Levy-Nissenbaum E.
40
Coauthors
5
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2007 | 2 |
| 2008 | 1 |
| 2012 | 1 |
| 2013 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Cáncer | 8 |
| Nanopartícula | 1 |
| Biomedicina | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Farmacología y terapéutica | 5 |
| Enfermedades | 3 |
| Medicina y salud | 2 |
| Física aplicada | 1 |
| Ingeniería civil | 1 |
| Ingeniería y operaciones afines | 1 |
| Fisiología y materias afines | 1 |
| Fisiología humana | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 5 |
| Google Scholar | 0 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Frank Alexis | 5 |
| Farokhzad O.C. | 5 |
| Langer R.S. | 4 |
| Pridgen E.M. | 2 |
| Basto P.A. | 2 |
| Radovic-Moreno A.F. | 2 |
| Wang A.Z. | 2 |
| Gu F.X. | 2 |
| Karnik R. | 2 |
| Cheng J. | 1 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Targeted nanoparticle-polypeptide bioconjugates for breast cancer therapy
Conference ObjectAbstract: Novel approaches that allow for a more effective and less toxic chemotherapy for disseminated breastPalabras claves:Docetaxel, HER2, Pla, Poly (lactic acid), Targeted nanoparticlesAutores:Basto P.A., Farokhzad O.C., Frank Alexis, Gu F.X., Langer R.S., Levy-Nissenbaum E., Radovic-Moreno A.F.Fuentes:scopusTransepithelial transport of Fc-targeted nanoparticles by the neonatal Fc receptor for oral delivery
ArticleAbstract: Nanoparticles are poised to have a tremendous impact on the treatment of many diseases, but their brPalabras claves:Autores:Blumberg R., Farokhzad O.C., Frank Alexis, Karnik R., Kuo T., Langer R.S., Levy-Nissenbaum E., Pridgen E.M.Fuentes:scopusTargeted nanoparticles for cancer therapy
ArticleAbstract: Over the past decade, there has been an increasing interest in using nanotechnology for cancer theraPalabras claves:Autores:Farokhzad O.C., Frank Alexis, Gu F.X., Hong S., Karnik R., Langer R.S., Levy-Nissenbaum E., Wang A.Z.Fuentes:scopusEngineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection
ArticleAbstract: Figure Persented: One of the major challenges in the development of targeted nanoparticles (NPs) forPalabras claves:aptamer, in vitro selection, Internalization, Nanoparticles, targeted cancer therapyAutores:Chan J.M., Cheng J., Digga E., Farokhzad O.C., Frank Alexis, Langer R.S., Levy-Nissenbaum E., Lupták A., Shi J., Teply B.A., Xiao Z.Fuentes:scopusHER-2-targeted nanoparticle-affibody bioconjugates for cancer therapy
ArticleAbstract: (Figure Presented) Affibodies are a class of polypeptide ligand that are potential candidates for tiPalabras claves:Affibodies, Antitumor agents, Nanoparticles, PLA-PEG copolymers, Targeted therapyAutores:Basto P.A., Farokhzad O.C., Frank Alexis, Levy-Nissenbaum E., Marein S.L., Molnar L.K., Pridgen E.M., Radovic-Moreno A.F., Wang A.Z., Westerhof K., Zhang L.Fuentes:scopus